A robust clinical pipeline of Tumor Defence Breakers (DOS47) and Tumor Defence Attackers (CAR-T).

Our most advanced Tumor Defence Breaker, L-DOS47, is currently in clinical trials for the treatment of non squamous small cell lung cancer (NSCLC). The application of L-DOS47 in other disease indication such as colon, pancreas and breast cancer is also being considered. A second DOS47 candidate known as V-DOS47 targets the vascular epithelial growth factor receptor 2 is at preclinical development.

Helix is also developing a number of Tumor Attackers, CAR-T, that are potential treatment of hematological and solid tumors.

Learn more about our ongoing clinical trials at www.clinicaltrials.gov.

image3

Tumor Defence Breaker

L-DOS47 monotherapy NSCLC (ongoing)

PRECLINICAL
PHASE 1
PHASE 2

L-DOS47 combination NSCLC (ongoing)

PRECLINICAL
PHASE 1
PHASE 2

L-DOS47 Combo Other Indications

PRECLINICAL
PHASE 1
PHASE 2

L-DOS47 Combo Immune Checkpoints

PRECLINICAL
PHASE 1
PHASE 2

V-DOS47

PRECLINICAL
PHASE 1
PHASE 2

Immuno Oncology

CAR-T Solid Tumors (CEACAM6)

PRECLINICAL
PHASE 1
PHASE 2

CAR-T Hematologic Tumors (Bispecific)

PRECLINICAL
PHASE 1
PHASE 2